News
Versameb to present novel data on its lead asset, VMB-100 at 9th International mRNA Health Conference
VMB-100 shows therapeutic potential in Stress Urinary Incontinence
…
Phebra Acquires Equity Stake in UK Specialty Hospital Pharma Company Flexipharm Austrading
- Phebra takes part ownership of Flexipharm Austrading through…
Verona Pharma Announces November 2021 Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona…
Muna Therapeutics appoints Dr. Niels Plath as Chief Scientific Officer
Brings more than 15 years of CNS drug discovery and development…
Arix Bioscience: Aura Biosciences prices Nasdaq IPO
LONDON, 29 October 2021: Arix Bioscience plc (LSE: ARIX, "Arix"),…
eTheRNA immunotherapies conference attendance for November 2021
eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage…
Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E™-Based ADCs
Winning scientific poster shows complete tumor regression…
Futura Medical plc Board Appointment
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
Synendos Therapeutics Appoints Scientific Advisory Board
Synendos Therapeutics is thrilled to announce the formation of…
Synendos Therapeutics Appoints Scientific Advisory Board
Synendos Therapeutics is thrilled to announce the formation of…
The DayOne Digital Health Accelerator Program
DayOne focus on healthcare innovation driven by digital health…
Leucid Bio Raises £11.5M in Series A Financing to Develop Next Generation of Innovative Chimeric Antigen Receptor T cell (CAR-T) Therapies
London, UK – 21 October 2021 - Leucid Bio (“Leucid” or…
ONA Therapeutics Strengthens Scientific Leadership Team
Industry veteran in oncology antibody discovery & development…
Novo Holdings Leads US$21M Series A Financing in BI-OMILQ
Funds will be used to support the development of pioneering…
LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
October 18, 2021
Early data from Phase 1/2 clinical trial…
Pyxis Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pyxis…
Arix Bioscience plc Business Update and Cancellation of Share Buyback
LONDON, 18 October 2021: Arix Bioscience plc (“Arix” or the…
Destiny Pharma: Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus
Major US hospital-based clinical trial highlights benefit of…
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
ALAMEDA, Calif. & CAMBRIDGE, UK – October 14, 2021 – Exelixis,…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
